Plain-English translation of NCT02543710 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
MoMaTEC2 is testing whether specific markers found in tumor tissue can help doctors decide which surgical procedures and chemotherapy treatments work best for each person with endometrial cancer. The study has two main parts: one focuses on using biomarkers to guide surgery decisions, and the other tests whether a marker called stathmin can predict how well a chemotherapy drug called paclitaxel will work.
Currently, doctors treat endometrial cancer using standard approaches for all patients, but these don't work equally well for everyone. This trial aims to identify tumor markers that could help doctors personalize treatment — removing only the lymph nodes that need to be removed and choosing chemotherapy that's more likely to help each individual patient.
You likely qualify if…
You likely don't qualify if…
If you join Part 1, your tumor tissue will be tested for biomarkers to help guide your surgical treatment, and your doctors will track your outcomes over time. If you join Part 2, you will have a new tissue biopsy taken to measure stathmin levels in your tumor, and this information will be used alongside your routine chemotherapy treatment to see if it predicts how well the medication works for you. Both parts involve sharing your medical information and allowing researchers to study your tumor samples.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Netherlands
Norway